Drug Cardiology

Opsumit

Payments companies reported to CMS as associated with Opsumit. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$11Massociated payments (2023-2025)

20,585clinicians with associated payments

7companies reporting

By year

2023 $3.8M

2024 $4.1M

2025 $3.6M

Payments reported as associated with Opsumit, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Pulmonary Disease $3.9M

Cardiovascular Disease $2.4M

Advanced Heart Failure and Transplant Cardiology $1.5M

Critical Care Medicine (Internal Medicine) $1.1M

Internal Medicine $426K

Family $393K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Opsumit

These are the largest totals companies reported as associated with Opsumit. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
John Ryan	Salt Lake City, UT	Cardiovascular Disease	$349,645.14
Hunter Champion	Columbus, GA	Cardiovascular Disease	$302,054.49
Omar Minai	Hopewell, VA	Pulmonary Disease	$276,250.07
Neal Chaisson	Cleveland, OH	Critical Care Medicine (Internal Medicine)	$264,392.86
John Mcconnell	Louisville, KY	Pulmonary Disease	$242,448.56
Paul Forfia	Philadelphia, PA	Cardiovascular Disease	$235,526.98
Ashish Gupta	Phoenix, AZ	Cardiovascular Disease	$203,614.78
Hyong Kim	La Jolla, CA	Internal Medicine	$201,636.17
Anjali Vaidya	Philadelphia, PA	Advanced Heart Failure and Transplant Cardiology	$180,536.92
Abhijit Raval	Anderson, SC	Pulmonary Disease	$167,156.55

Prescribed Opsumit?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.